<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03870243</url>
  </required_header>
  <id_info>
    <org_study_id>PR-18052</org_study_id>
    <nct_id>NCT03870243</nct_id>
  </id_info>
  <brief_title>Feasibility and Acceptability Followed by Effectiveness of bCPAP for Treatment of Children Aged 1-59 Months With Severe Pneumonia in Ethiopia</brief_title>
  <official_title>Feasibility and Acceptability Followed by Effectiveness of Bubble Continuous Positive Airway Pressure (bCPAP) for Treatment of Children Aged 1-59 Months With Severe Pneumonia in Ethiopia: A Cluster Randomized Controlled Clinical Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>International Centre for Diarrhoeal Disease Research, Bangladesh</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Armauer Hansen Research Institute (AHRI), Ethiopia</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>International Centre for Diarrhoeal Disease Research, Bangladesh</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Principal Investigator: Mohammod Jobayer Chisti&#xD;
&#xD;
      Research Protocol Title: Feasibility and Acceptability Followed by Effectiveness of Bubble&#xD;
      Continuous Positive Airway Pressure (bCPAP) for Treatment of Children aged 1-59 months with&#xD;
      Severe Pneumonia in Ethiopia: A Cluster Randomized Controlled Clinical Trial&#xD;
&#xD;
      Proposed start date: 1st July 2018, Estimated end date: 31st December 2022&#xD;
&#xD;
      Background: Feasibility and acceptability followed by effectiveness of bubble continuous&#xD;
      positive airway pressure (CPAP) were not evaluated in childhood severe pneumonia in&#xD;
      developing countries at a larger scale.&#xD;
&#xD;
      Objectives:&#xD;
&#xD;
      Stages I and II&#xD;
&#xD;
        -  To assess the feasibility and acceptability (not only by patients' care-givers but also&#xD;
           by physicians and nurses) of bubble CPAP in treating childhood severe pneumonia in two&#xD;
           tertiary hospitals in Stage I and in two district hospitals in Stage II&#xD;
&#xD;
        -  To record adverse events following use of bubble CPAP in these settings&#xD;
&#xD;
        -  To understand how much resource and time are needed to institutionalize and maintain&#xD;
           bubble CPAP as a routine practice in the health system&#xD;
&#xD;
      Stage III:&#xD;
&#xD;
        -  To determine therapeutic efficacy/effectiveness of bubble CPAP compared to WHO standard&#xD;
           low flow oxygen in reducing treatment failure in children admitted to hospitals with&#xD;
           severe pneumonia and hypoxemia&#xD;
&#xD;
        -  To determine therapeutic effectiveness of bubble CPAP compared to WHO standard low flow&#xD;
           oxygen in reducing treatment failure &amp; mortality in children aged 1-12 months admitted&#xD;
           to hospitals with severe pneumonia and hypoxemia&#xD;
&#xD;
        -  To record adverse events (pneumothorax, abdominal distension, nasal trauma, aspiration&#xD;
           pneumonia) encountered.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Methodology:&#xD;
&#xD;
      Cluster randomized controlled clinical trial&#xD;
&#xD;
      Methodology:&#xD;
&#xD;
        1. Stages I and II: Feasibility/demonstration stage will be done as an internal pilot in 3&#xD;
           hospitals&#xD;
&#xD;
           a. Current treatment practice, facilities, and operational challenges will be evaluated&#xD;
           for the introduction, clinical use and maintenance of bubble CPAP&#xD;
&#xD;
        2. Stage III: Implementation of bubble CPAP will be done in 12 hospitals a. It will be done&#xD;
           following a cluster randomized design&#xD;
&#xD;
      Data collection-socio-demographic and clinical data will be collected using structured&#xD;
      questionnaire by trained nurses and physicians.&#xD;
&#xD;
      Research Site:&#xD;
&#xD;
      St. Paulos Millennium Medical College, Yekatit 12 and Tikur Anbessa Specialized hospitals, 14&#xD;
      district hospitals&#xD;
&#xD;
      Number of Participants/Patients:&#xD;
&#xD;
      Stage I-30 children in each tertiary hospital (this stage has completed and we enrolled 49&#xD;
      children from two tertiary hospitals; these 49 enrolled children took double of our&#xD;
      anticipated time {4 months}) Stage II- 20 children in each general hospital (2&#xD;
      general/district hospitals, we have enrolled total 40 children from this two hospitals from&#xD;
      January 2020 to July 2020, which included COVID-19 period) Stage III-1240 children in 12&#xD;
      general/district hospitals (620 in bubble CPAP arm and 620 in WHO standard low flow arm; each&#xD;
      hospital will be the cluster and 6 will be randomized to each arm)&#xD;
&#xD;
      Main Inclusion Criteria:&#xD;
&#xD;
        -  Age between 1 month and 59 months&#xD;
&#xD;
        -  Meet WHO clinical criteria for severe pneumonia with hypoxemia&#xD;
&#xD;
        -  Hypoxemia (Oxygen saturation &lt;90% in room air)&#xD;
&#xD;
        -  Parent/guardian gives informed consent to participate in the study&#xD;
&#xD;
      Statistical Analysis:&#xD;
&#xD;
        -  STATA -14: for initial two phases descriptive analysis of level of feasibility and&#xD;
           acceptability will be performed&#xD;
&#xD;
        -  For the phase III: We shall follow the principle of intention to treat. --Treatment&#xD;
           failure and/or death will be analyzed using χ² or Fisher's exact tests as appropriate.&#xD;
&#xD;
        -  Primary and secondary outcomes will be compared by calculating relative risks (RRs) and&#xD;
           their 95% confidence intervals.&#xD;
&#xD;
        -  Log-linear binomial regression will be applied to adjust for covariates to evaluate the&#xD;
           true impact of bubble CPAP in evaluating primary and secondary outcomes and to adjust&#xD;
           for baseline differences.&#xD;
&#xD;
        -  Continuous variables will be analyzed using the Student t-test or the Mann-Whitney test&#xD;
           as appropriate.&#xD;
&#xD;
      Study Duration:&#xD;
&#xD;
      48 months.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">September 2, 2019</start_date>
  <completion_date type="Anticipated">December 31, 2022</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2022</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Children aged 1-59 months with Severe Pneumonia in Ethiopia, divided in two arms; one arm will get bCPAP other arm will get WHO recommended low flow oxygen.</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
    <masking_description>In stage III among 12 district hospitals, 6 hospitals will randomly selected for bubble CPAP and another 6 hospitals will get low flow oxygen therapy. Masking of the personnel who are related to the study will be maintained from beginning.</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>For stage I and II feasibility and acceptability of bubble CPAP in two tertiary and two district hospitals will be measured in number and reported in percentage</measure>
    <time_frame>7 months</time_frame>
    <description>Patient level and health professional level challenge is the outcome of phase I and II. All will be measured in number and reported in percentage. For stage I and II: Primary outcome: operational challenges that may include availability of pulse oxymetry, IV cannula, IV antibiotics, oxygen supply system and nasal catheters for treating severe pneumonia Secondary outcomes: prevalence of severe pneumonia associated hypoxemia, their treatment practices, adverse events, mortality and treatment failure</description>
  </primary_outcome>
  <primary_outcome>
    <measure>For stage III: Primary outcome: Treatment failure</measure>
    <time_frame>12-18 months (Mid April 2021 to Mid October 2022)</time_frame>
    <description>According to this protocol treatment failure will be declared if the following criteria are met:&#xD;
A. Presence of severe hypoxemia (SpO2&lt;85%) at any time after at least one hour of intervention plus severe respiratory distress when the child is receiving BCPAP/LF OR, B. If the patient developed the indication of mechanical ventilation when the child is receiving BCPAP/LF OR, C. If the patient died during hospitalization OR, D. If the patient left against medical advice (LAMA) due to lack of improvement or deterioration of the child during hospitalization&#xD;
All will be measured in number and reported in percentage.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Secondary outcomes: • Death • Adverse events (pneumothorax, abdominal distension, nasal trauma, aspiration pneumonia ) encountered</measure>
    <time_frame>12-18 months (Mid April 2021 to Mid October 2022)</time_frame>
    <description>All will be measured in number and reported in percentage.</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Length of hospital stay in days</measure>
    <time_frame>12-18 months (Mid April 2021 to Mid October 2022)</time_frame>
    <description>Length of hospital stay will be measured and reported in days.</description>
  </other_outcome>
  <other_outcome>
    <measure>Incidence of nasal trauma, gastric distention, shock and air leaks in number</measure>
    <time_frame>12-18 months (Mid April 2021 to Mid October 2022)</time_frame>
    <description>Incidence of nasal trauma, gastric distention, shock and air leaks will be measured in number and reported in percentage.</description>
  </other_outcome>
  <other_outcome>
    <measure>Duration of bCPAP in hour</measure>
    <time_frame>12-18 months (Mid April 2021 to Mid October 2022)</time_frame>
    <description>Duration of bCPAP will be measured and reported in hour/hours.</description>
  </other_outcome>
  <other_outcome>
    <measure>Acceptability of bCPAP by nurses and physicians will be measured in number and reported in percentage</measure>
    <time_frame>12-18 months (Mid April 2021 to Mid October 2022)</time_frame>
    <description>Acceptability of bCPAP by nurses and physicians will be measured in number and reported in percentage.</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">1240</enrollment>
  <condition>Severe Pneumonia</condition>
  <arm_group>
    <arm_group_label>Bubble CPAP</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>6 hospitals will be selected randomly for this arm</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Low flow oxygen</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>6 hospitals will be selected for low flow oxygen therapy</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Bubble CPAP</intervention_name>
    <description>To see the effectiveness of Bubble Continuous Positive Airway Pressure (bCPAP) in children with severe pneumonia</description>
    <arm_group_label>Bubble CPAP</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Low flow oxygen</intervention_name>
    <description>To see the effectiveness of low flow oxygen in children with severe pneumonia</description>
    <arm_group_label>Low flow oxygen</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Age between 1 month and 59 months,&#xD;
&#xD;
          -  Meet WHO clinical criteria for severe pneumonia with hypoxemia.&#xD;
&#xD;
          -  Oxygen saturation &lt;90% despite standard flow oxygen therapy&#xD;
&#xD;
          -  Parent/guardian gives informed consent to participate in the study&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Known congenital heart disease, asthma, or upper -airway obstruction&#xD;
&#xD;
          -  Tracheostomy&#xD;
&#xD;
          -  Pneumothorax&#xD;
&#xD;
          -  Needs mechanical ventilation for any specific reason as decided by the clinician&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>1 Month</minimum_age>
    <maximum_age>59 Months</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Mohammod Jobayer Chisti, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>International Centre for Diarrhoeal Disease Research, Bangladesh</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Mohammod Jobayer Chisti, PhD</last_name>
    <phone>+88-29827084</phone>
    <phone_ext>2334</phone_ext>
    <email>chisti@icddrb.org</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Meseret Gebre Behute, MD</last_name>
    <phone>251 911977885</phone>
    <email>mesibire@yahoo.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>International Centre for Diarrhoeal Disease Research, Bangladesh (icddr,b)</name>
      <address>
        <city>Dhaka</city>
        <state>Mohakhali</state>
        <zip>1212</zip>
        <country>Bangladesh</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mohammod Jobayer Chisti, PhD</last_name>
    </contact>
  </location>
  <location_countries>
    <country>Bangladesh</country>
  </location_countries>
  <reference>
    <citation>UNICEF. Committing to Child Survival: A Promise Renewed. Progress Report 2015 2015</citation>
  </reference>
  <reference>
    <citation>Liu L, Oza S, Hogan D, Perin J, Rudan I, Lawn JE, Cousens S, Mathers C, Black RE. Global, regional, and national causes of child mortality in 2000-13, with projections to inform post-2015 priorities: an updated systematic analysis. Lancet. 2015 Jan 31;385(9966):430-40. doi: 10.1016/S0140-6736(14)61698-6. Epub 2014 Sep 30. Erratum in: Lancet. 2015 Jan 31;385(9966):420. Erratum in: Lancet. 2016 Jun 18;387(10037):2506.</citation>
    <PMID>25280870</PMID>
  </reference>
  <reference>
    <citation>You D, Hug L, Ejdemyr S, Idele P, Hogan D, Mathers C, Gerland P, New JR, Alkema L; United Nations Inter-agency Group for Child Mortality Estimation (UN IGME). Global, regional, and national levels and trends in under-5 mortality between 1990 and 2015, with scenario-based projections to 2030: a systematic analysis by the UN Inter-agency Group for Child Mortality Estimation. Lancet. 2015 Dec 5;386(10010):2275-86. doi: 10.1016/S0140-6736(15)00120-8. Epub 2015 Sep 8. Erratum in: Lancet. 2015 Dec 5;386(10010):2256.</citation>
    <PMID>26361942</PMID>
  </reference>
  <reference>
    <citation>Graham SM, English M, Hazir T, Enarson P, Duke T. Challenges to improving case management of childhood pneumonia at health facilities in resource-limited settings. Bull World Health Organ. 2008 May;86(5):349-55. Review.</citation>
    <PMID>18545737</PMID>
  </reference>
  <reference>
    <citation>Rahman AE, Moinuddin M, Molla M, Worku A, Hurt L, Kirkwood B, Mohan SB, Mazumder S, Bhutta Z, Raza F, Mrema S, Masanja H, Kadobera D, Waiswa P, Bahl R, Zangenberg M, Muhe L; Persistent Diarrhoea Research Group. Childhood diarrhoeal deaths in seven low- and middle-income countries. Bull World Health Organ. 2014 Sep 1;92(9):664-71. doi: 10.2471/BLT.13.134809. Epub 2014 Jun 23.</citation>
    <PMID>25378757</PMID>
  </reference>
  <reference>
    <citation>Duke T, Tamburlini G, Silimperi D; Paediatric Quality Care Group. Improving the quality of paediatric care in peripheral hospitals in developing countries. Arch Dis Child. 2003 Jul;88(7):563-5. Erratum in: Arch Dis Child. 2003 Oct;88(10):946.</citation>
    <PMID>12818896</PMID>
  </reference>
  <reference>
    <citation>Duke T, Peel D, Graham S, Howie S, Enarson PM, Jacobson R. Oxygen concentrators: a practical guide for clinicians and technicians in developing countries. Ann Trop Paediatr. 2010;30(2):87-101. doi: 10.1179/146532810X12637745452356. Review.</citation>
    <PMID>20522295</PMID>
  </reference>
  <reference>
    <citation>McKiernan C, Chua LC, Visintainer PF, Allen H. High flow nasal cannulae therapy in infants with bronchiolitis. J Pediatr. 2010 Apr;156(4):634-8. doi: 10.1016/j.jpeds.2009.10.039. Epub 2009 Dec 29.</citation>
    <PMID>20036376</PMID>
  </reference>
  <reference>
    <citation>Schibler A, Pham TM, Dunster KR, Foster K, Barlow A, Gibbons K, Hough JL. Reduced intubation rates for infants after introduction of high-flow nasal prong oxygen delivery. Intensive Care Med. 2011 May;37(5):847-52. doi: 10.1007/s00134-011-2177-5. Epub 2011 Mar 3.</citation>
    <PMID>21369809</PMID>
  </reference>
  <reference>
    <citation>Duke T. CPAP: a guide for clinicians in developing countries. Paediatr Int Child Health. 2014 Feb;34(1):3-11. doi: 10.1179/2046905513Y.0000000102. Epub 2013 Dec 6. Review.</citation>
    <PMID>24165032</PMID>
  </reference>
  <reference>
    <citation>Chisti MJ, Salam MA, Smith JH, Ahmed T, Pietroni MA, Shahunja KM, Shahid AS, Faruque AS, Ashraf H, Bardhan PK, Sharifuzzaman, Graham SM, Duke T. Bubble continuous positive airway pressure for children with severe pneumonia and hypoxaemia in Bangladesh: an open, randomised controlled trial. Lancet. 2015 Sep 12;386(9998):1057-65. doi: 10.1016/S0140-6736(15)60249-5. Epub 2015 Aug 19.</citation>
    <PMID>26296950</PMID>
  </reference>
  <reference>
    <citation>Koti J, Murki S, Gaddam P, Reddy A, Reddy MD. Bubble CPAP for respiratory distress syndrome in preterm infants. Indian Pediatr. 2010 Feb;47(2):139-43. Epub 2009 May 20.</citation>
    <PMID>19578226</PMID>
  </reference>
  <reference>
    <citation>Chisti MJ, Duke T, Ahmed T, Shahunja KM, Shahid ASMSB, G. FAS, et al. The Use of Bubble CPAP and Humidified High Flow Nasal Cannula Oxygen Therapy in Children with Severe Pneumonia and Hypoxemia: A Systematic Review of the Evidence. Bangladesh Crit Care J. 2014; 2:71-8</citation>
  </reference>
  <reference>
    <citation>Liptsen E, Aghai ZH, Pyon KH, Saslow JG, Nakhla T, Long J, Steele AM, Habib RH, Courtney SE. Work of breathing during nasal continuous positive airway pressure in preterm infants: a comparison of bubble vs variable-flow devices. J Perinatol. 2005 Jul;25(7):453-8.</citation>
    <PMID>15858606</PMID>
  </reference>
  <reference>
    <citation>Courtney SE, Kahn DJ, Singh R, Habib RH. Bubble and ventilator-derived nasal continuous positive airway pressure in premature infants: work of breathing and gas exchange. J Perinatol. 2011 Jan;31(1):44-50. doi: 10.1038/jp.2010.55. Epub 2010 Apr 15.</citation>
    <PMID>20393478</PMID>
  </reference>
  <reference>
    <citation>van den Heuvel M, Blencowe H, Mittermayer K, Rylance S, Couperus A, Heikens GT, Bandsma RH. Introduction of bubble CPAP in a teaching hospital in Malawi. Ann Trop Paediatr. 2011;31(1):59-65. doi: 10.1179/1465328110Y.0000000001.</citation>
    <PMID>21262111</PMID>
  </reference>
  <reference>
    <citation>Buckmaster AG, Arnolda G, Wright IM, Foster JP, Henderson-Smart DJ. Continuous positive airway pressure therapy for infants with respiratory distress in non tertiary care centers: a randomized, controlled trial. Pediatrics. 2007 Sep;120(3):509-18. Erratum in: Pediatrics.2008 Jun;121(6): 1301.</citation>
    <PMID>17766523</PMID>
  </reference>
  <reference>
    <citation>Kinikar A, Kulkarni R, Valvi C, Gupte N. Use of indigenous bubble CPAP during swine flu pandemic in Pune, India. Indian J Pediatr. 2011 Oct;78(10):1216-20. doi: 10.1007/s12098-011-0389-x. Epub 2011 Mar 26.</citation>
    <PMID>21442266</PMID>
  </reference>
  <reference>
    <citation>Tagare A, Kadam S, Vaidya U, Pandit A, Patole S. A pilot study of comparison of BCPAP vs. VCPAP in preterm infants with early onset respiratory distress. J Trop Pediatr. 2010 Jun;56(3):191-4. doi: 10.1093/tropej/fmp092. Epub 2009 Oct 20.</citation>
    <PMID>19843596</PMID>
  </reference>
  <reference>
    <citation>Daga S, Mhatre S, Borhade A, Khan D. Home-made continuous positive airways pressure device may reduce mortality in neonates with respiratory distress in low-resource setting. J Trop Pediatr. 2014 Oct;60(5):343-7. doi: 10.1093/tropej/fmu023. Epub 2014 Apr 23.</citation>
    <PMID>24760748</PMID>
  </reference>
  <reference>
    <citation>Koyamaibole L, Kado J, Qovu JD, Colquhoun S, Duke T. An evaluation of bubble-CPAP in a neonatal unit in a developing country: effective respiratory support that can be applied by nurses. J Trop Pediatr. 2006 Aug;52(4):249-53. Epub 2005 Dec 2.</citation>
    <PMID>16326752</PMID>
  </reference>
  <reference>
    <citation>Yagui AC, Vale LA, Haddad LB, Prado C, Rossi FS, Deutsch AD, Rebello CM. Bubble CPAP versus CPAP with variable flow in newborns with respiratory distress: a randomized controlled trial. J Pediatr (Rio J). 2011 Nov-Dec;87(6):499-504. doi: 10.2223/JPED.2145.</citation>
    <PMID>22170173</PMID>
  </reference>
  <reference>
    <citation>Wilson PT, Morris MC, Biagas KV, Otupiri E, Moresky RT. A randomized clinical trial evaluating nasal continuous positive airway pressure for acute respiratory distress in a developing country. J Pediatr. 2013 May;162(5):988-92. doi: 10.1016/j.jpeds.2012.10.022. Epub 2012 Nov 16.</citation>
    <PMID>23164308</PMID>
  </reference>
  <reference>
    <citation>Federal Democratic Republic of Ethiopia Ministry of Health. Integrated Management of Newborn and Childhood Illness, Part 1 Blended Learning Module for the Health Extension Programme</citation>
  </reference>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>March 6, 2019</study_first_submitted>
  <study_first_submitted_qc>March 7, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">March 12, 2019</study_first_posted>
  <last_update_submitted>October 22, 2021</last_update_submitted>
  <last_update_submitted_qc>October 22, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 29, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Bubble CPAP</keyword>
  <keyword>Young Children</keyword>
  <keyword>Severe Pneumonia</keyword>
  <keyword>Hypoxemia</keyword>
  <keyword>Treatment failure</keyword>
  <keyword>Mortality</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pneumonia</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
    <ipd_description>We will share the final outcome after completing the study</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

